Serum markers of fibrosis, cardiovascular and all-cause mortality in hemodialysis patients: the AURORA trial.
Fiche publication
Date publication
juin 2021
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Salib M, Girerd S, Girerd N, März W, Scharnagl H, Massy ZA, Leroy C, Duarte K, Holdaas H, Jardine AG, Schmieder RE, Fellström B, López-Andrés N, Rossignol P, Zannad F
Lien Pubmed
Résumé
Biomarkers of fibrosis are associated with outcome in several cardiovascular diseases. However, their relevance to chronic kidney disease and dialysis is uncertain, as it remains unclear how the kidneys and the dialysis procedure itself affect their elimination and degradation. We aimed to investigate the relationship of the blood levels of two markers associated with fibrosis: procollagen type I C-terminal pro-peptide (PICP) and galectin-3 (Gal-3) with mortality in dialysis patients.
Mots clés
Biomarker, Cardiovascular diseases, Collagen, Fibrosis, Galectin-3, Hemodialysis
Référence
Clin Res Cardiol. 2021 Jun 25;: